Literature DB >> 6265964

Studies on possible mechanisms of action of electroconvulsive therapy; effects of repeated electrically induced seizures on rat brain receptors for monoamines and other neurotransmitters.

J F Deakin, F Owen, A J Cross, M J Dashwood.   

Abstract

There is evidence that repeated electroconvulsive shocks (ECS) in rats potentiate dopamine (DA)-, serotonin (5HT)- and alpha-noradrenergic (alpha-NA)-mediated drug-induced behaviour and reduce opiate-induced behaviours. These studies suggest changes at the level of the receptor or beyond. However, high affinity in vitro 3H-ligand binding studies in brain membranes from ECS-treated control rats failed to demonstrate generalized ECS-induced changes in 5HT, DA, alpha-NA or opiate receptor binding. Binding of the beta-receptor ligand dihydroalprenolol (3H-DHA) was significantly reduced in ECS-treated rat brain membranes. This may be secondary to effects on NA neurones since ECS-induced reduction of 3H-DHA binding did not occur in animals with 6-hydroxydopamine-induced depletion of cortical noradrenaline. In conjunction with other studies, the results suggest that electroconvulsive therapy may have a noradrenergic mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265964     DOI: 10.1007/bf00426463

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.

Authors:  D A Greenberg; D C Prichard; S H Snyder
Journal:  Life Sci       Date:  1976-07-01       Impact factor: 5.037

2.  Properties of 3H-diazepam binding to benzodiazepine receptors in rat cerebral cortex.

Authors:  H Möhler; T Okada
Journal:  Life Sci       Date:  1977-06-15       Impact factor: 5.037

3.  Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain.

Authors:  D A Bergstrom; K J Kellar
Journal:  Nature       Date:  1979-03-29       Impact factor: 49.962

4.  Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain.

Authors:  J Vetulani; F Sulser
Journal:  Nature       Date:  1975-10-09       Impact factor: 49.962

5.  Development of beta-adrenergic receptor subsensitivity by antidepressants.

Authors:  S P Banerjee; L S Kung; S J Riggi; S K Chanda
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

6.  Effects of apomorphine and clonidine on rat plasma growth hormone after pretreatment with reserpine and electroconvulsive shocks.

Authors:  S Edén; K Modigh
Journal:  Brain Res       Date:  1977-07-01       Impact factor: 3.252

7.  Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs.

Authors:  J P Evans; D G Grahame-Smith; A R Green; A F Tordoff
Journal:  Br J Pharmacol       Date:  1976-02       Impact factor: 8.739

Review 8.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

9.  Long-term effects of electroconvulsive shock therapy on synthesis, turnover and uptake of brain monoamines.

Authors:  K Modigh
Journal:  Psychopharmacology (Berl)       Date:  1976-09-17       Impact factor: 4.530

10.  The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

Authors:  J F Deakin; A R Green
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

View more
  17 in total

Review 1.  Antidepressants and serotonergic neurotransmission: an integrative review.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Effects of chronic electroconvulsive shock on interstitial concentrations of dopamine in the nucleus accumbens.

Authors:  G G Nomikos; A P Zis; G Damsma; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat.

Authors:  G W Bennett; A R Green; C Lighton; C A Marsden
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

4.  Classification of drugs according to receptor binding profiles.

Authors:  A Closse; W Frick; A Dravid; G Bolliger; D Hauser; A Sauter; H J Tobler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

Review 5.  Can drugs cause depression? A review of the evidence.

Authors:  S B Patten; E J Love
Journal:  J Psychiatry Neurosci       Date:  1993-05       Impact factor: 6.186

6.  Changes in noradrenergic neuroendocrine responses following repeated seizures and the mechanism of action of ECT.

Authors:  J R McWilliam; B S Meldrum; S A Checkley
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.

Authors:  A Reches; H R Wagner; A I Barkai; V Jackson; E Yablonskaya-Alter; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Dopamine and serotonin metabolites in rat cerebroventricular fluid following withdrawal of haloperidol or electroshock treatment.

Authors:  A I Barkai; S Kowalik; A Reches
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Brain 5-hydroxytryptamine level, metabolism, and binding in E1 mice.

Authors:  M Hiramatsu
Journal:  Neurochem Res       Date:  1983-09       Impact factor: 3.996

10.  Antidepressant treatments: effects in rodents on dose-response curves of 5-hydroxytryptamine- and dopamine-mediated behaviours and 5-HT2 receptor number in frontal cortex.

Authors:  A R Green; D J Heal; P Johnson; B E Laurence; V L Nimgaonkar
Journal:  Br J Pharmacol       Date:  1983-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.